Cancer Research Prevention Award Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4574-4577, September 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daniel, T. O.
Right arrow Articles by Marnett, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daniel, T. O.
Right arrow Articles by Marnett, L. J.
[Cancer Research 59, 4574-4577, September 15, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Thromboxane A2 Is a Mediator of Cyclooxygenase-2-dependent Endothelial Migration and Angiogenesis1

Thomas O. Daniel2, Hua Liu, Jason D. Morrow, Brenda C. Crews and Lawrence J. Marnett

Departments of Medicine, Cell Biology, Biochemistry, and Pharmacology, Divisions of Nephrology and Hypertension and Clinical Pharmacology, The Vanderbilt Center for Vascular Biology, Vanderbilt Cancer Center, Vanderbilt University, Nashville, Tennessee 3723


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
Cyclooxygenase-2 (COX-2) inhibitors reduce angiogenic responses to a variety of stimuli, suggesting that products of COX-2 may mediate critical steps. Here, we show that thromboxane A2 (TXA2) is one of several eicosanoid products generated by activated human microvascular endothelial cells. Selective COX-2 antagonists inhibit TXA2 production, endothelial migration, and fibroblast growth factor-induced corneal angiogenesis. Endothelial migration and corneal angiogenesis are similarly inhibited by a TXA2 receptor antagonist, SQ29548. A TXA2 agonist, U46619, reconstitutes both migration and angiogenesis responses under COX-2-inhibited conditions. These findings identify TXA2 as a COX-2 product that functions as a critical intermediary of angiogenesis.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
Recent evidence suggests that COX-23 metabolic products contribute to neovascularization and may support vasculature-dependent solid tumor growth and metastasis. Selective COX-2 inhibitors are antiangiogenic (1) , and COX-2-null mice are substantially protected in a genetic model of human familial adenomatous polyposis (2) . Forced COX-2 overexpression enhances the metastatic potential of CaCo-2 colon carcinoma cells through processes that are sensitive to COX-2 inhibitors (3) . Coculture of endothelial cells with tumor cells promotes COX-2-dependent endothelial motility and assembly into capillary-like structures (4) , an effect that is attributed to tumor cell release of angiogenic peptides and nitric oxide. Alternatively, eicosanoids synthesized by endothelial COX-2 may contribute to this effect.

COX-2 expression or function is induced in cultured endothelial cells in response to phorbol esters (5 , 6) , basic FGF (7) , hypoxia (8) , cyclic strain (9) , thrombin, interleukin 1{alpha} (10) , or interleukin 1ß (11) . Hypoxia (12) or lipopolysaccharide administration (13) induce microvascular endothelial COX-2 expression in situ. Moreover, COX-2 inhibitors have been shown to decrease urinary excretion of prostacyclin, a major product of vascular endothelium in human subjects (14) . These findings motivated our efforts to identify a COX-2 product or products that are capable of functioning as intermediaries of angiogenesis.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Eicosanoids and Quantitation.
All of the eicosanoids and eicosanoid agonists were purchased from Cayman Chemical, (Ann Arbor, MI). Eicosanoids were quantified by gas chromatographic negative ion chemical ionization mass spectrometric assays using the precise and accurate stable isotope dilution technique (15) .

Endothelial Migration.
Confluent human renal microvascular endothelial cells were grown to confluency and serum-depleted in medium containing 1% (w/v) bovine albumin for 18 h prior to assay (16) . Triplicate circular "wounds" (600–900 µm in diameter) were generated in confluent endothelial monolayers within a single well, using a rotating silicon-tipped drill bit mounted on a drill press, to avoid scoring subjacent surfaces. Medium was supplemented at the time of wounding with test agents at concentrations indicated in the figures. Residual fractional wound areas were measured using a Bioquant (Nashville, TN) software package calibrated to a Nikon Diaphot microscope. Mean fractional residual areas of three wounds, calculated at each of two or three time points (see Fig. 1bCitation ), were used to derive linear regressions, reflecting migration rates (expressed as percentage closure per h ± 95% confidence intervals).



View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. a, COX-2-selective antagonist, VU08, inhibits PMA-induced eicosanoid production. Cultured human renal microvascular endothelial cells were exposed to vehicle ({square}), PMA ({blacksquare}; 20 ng/ml), or PMA supplemented with a COX-2 selective antagonist, VU08 (; 10 µM; IC50 against purified COX-2 was 50 nM; IC50 against purified COX-1 was 66 µM), for 8 h. Arachidonic acid (10 µM) was added, medium was collected after a 60-min incubation, and prostanoid products were quantified (15) . b, COX-2-selective inhibitor, VU08, inhibits PMA-induced endothelial migration. PMA-induced endothelial migration was assayed using a video capture/image analysis system (Bioquant, Nashville, TN) to follow the rate at which endothelial migration covered triplicate 600–900-µm-diameter circular wounds created in a confluent monolayer ("Materials and Methods"). At the time of wound initiation, medium was supplemented with vehicle ({circ}), PMA (20 ng/ml; •) or PMA with the COX-2 inhibitor, VU08 ({blacktriangleup}), at the concentrations indicated. Top inset, example of the residual wound areas remaining after 12 h incubation in cells treated with vehicle (top) or PMA (bottom). Data points, means of residual wound areas expressed as fractions of the original wound (Fractional Area) at 6, 9, and 12 h; bars, SE. Columns, migration rates, modeled by linear regression (r2 > 0.97 for each condition) and expressed as the percentage of the original wound area covered per hour; bars, 95% confidence limits (bottom inset). Two different COX-2 inhibitors, NS398 and VU08, inhibited the PMA induced migration rate. The effective IC50 was ~1 µM for VU08.

 
Mouse Corneal Angiogenesis Assay.
Hydron pellets incorporating sucralfate with vehicle alone, basic FGF (a kind gift from Scios, Inc.), or bFGF in combination with other agents indicated in the figure legends were surgically implanted into corneal stromal micropockets, created 1 mm medial to the lateral corneal limbus of C57BL mice (7–10 weeks old), as described previously (17) . On day 5, corneas were photographed at an incipient angle of 35–50° from the polar axis in the meridian containing the pellet, using a Zeiss slit lamp. Images were digitalized and processed by subtractive color filters (Adobe Photoshop Version 4.0), as displayed (see Figs. 3Citation and 4Citation ). Images were analyzed using Bioquant image analysis software to determine the fraction of the two-dimensional total corneal image that was vascularized and the fraction of pixels within that area (regional density) or within the corneal perimeter (total density) that exceeded a threshold matching visible capillaries.



View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. COX-2 inhibitor, VU08, and TXA2 receptor antagonist, SQ29548, attenuate FGF-induced corneal angiogenesis. a, hydron/sucralfate pellets impregnated with vehicle or basic FGF (3 pmol) were placed, as described previously (17) , in the corneal stroma of mice treated systemically by daily i.p. injection of vehicle (n = 4) or COX-2 inhibitor, VU08 (5 mg/kg; n = 8), beginning 1 day prior to implantation. Corneal angiogenic responses were photographed on day 5, and digitized images were quantified ("Materials and Methods"). COX-2 inhibition markedly attenuated (significant at P < 0.05) FGF-induced corneal angiogenesis, expressed as the fractional vascularized area, the regional vascular density (R), or the total vascular density (T). b, hydron/sucralfate pellets impregnated with vehicle, SQ29548 (1.5 nmol, n = 9), bFGF (3pmol, n = 9), or SQ29548 combined with bFGF (n = 9), were placed in the corneal stroma and evaluated on day 5, as above. SQ29548 attenuated FGF-induced angiogenesis by each parameter (significant at P < 0.05).

 


View larger version (42K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. TXA2 agonist, U46619, reconstitutes the COX-2 dependent FGF-induced angiogenic responses in vivo. Hydron/sucralfate pellets impregnated with vehicle (n = 4), U46619 (1.7 nmol, n = 6), bFGF (3pmol, n = 6) or bFGF supplemented with U46619 (1.7 nmol, n = 6) were placed in corneal pockets of animals treated daily by i.p. injection with either vehicle (left), or VU08 (5 mg/kg; right), beginning 1 day prior to implantation. Above, representative images are displayed from animals receiving FGF alone, or with the TXA2 receptor agonist, under COX-2 active (Vehicle) or COX-2 inhibited (COX-2 Inhibitor) conditions. Summarized data include fractional indices of the vascularized area (top) and regional vascular density within the vascularized area (bottom panels). Columns, means; bars, SE. U46619 addition to FGF pellet in VU08 treated mice (right) promotes an increase in regional vascular density and total vascular density (significant at P < 0.05).

 
The dose of VU08 used (5 mg/kg) was selected based on anti-inflammatory responses in a carrageenan foot pad assay and on effects of this dose to suppress TXA2 production by endogenous COX activity in prostate tumor tissue issue (85% inhibition at 3 days daily i.p. injection). Concentrations of SQ29548 were selected based on a dose-response experiment optimizing for inhibition of FGF-induced angiogenesis (data not shown).


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
Fig. 1aCitation provides the profile of eicosanoids produced by cultured microvascular endothelial cells under COX-2-induced conditions, following stimulation by PMA. Prostaglandin E2, TXA2 (measured indirectly as its thromboxane B2 metabolite), and prostaglandin F-2{alpha} were the dominant PMA-induced products, and induced endothelial production of each was blocked by coincident exposure to a COX-2-selective inhibitor. Notably, basal endothelial capacity to produce these metabolites was maintained in the presence of COX-2 inhibition, consistent with production by constitutive endothelial COX-1.

To assess functional consequences of endothelial COX-2 inhibition, we evaluated endothelial motility. The rates at which endothelial cell migration closed replicate circular wounds in confluent monolayers were determined by quantitating residual wound areas in digital images that were captured at multiple points during a 12-h time course. PMA reproducibly stimulated the rate of endothelial migration over that of untreated cells (Fig. 1b)Citation , and the PMA-induced migration was blocked by two different COX-2-selective inhibitors, NS398 and VU08.

The effect of COX-2 inhibition to reduce endothelial production of eicosanoids, coupled with its effect to inhibit endothelial migration, led us to ask whether supplementation with specific eicosanoids would reconstitute PMA-induced migration in the presence of COX-2 inhibition. Shown in Fig. 2aCitation , the TXA2 mimetic, U46619, reconstituted a near full migratory response to PMA under COX-2-inhibited conditions. Because endothelial cells produce TXA2 (Ref. 18 ; Fig. 1aCitation ) and express functional TXA2 receptors (19) , we evaluated further the effects of U46619 and the thromboxane receptor antagonist, SQ29548.



View larger version (30K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. a, TXA2 agonist, U46619, reconstituted PMA-induced endothelial migration during COX-2 inhibition. Endothelial migration rates (percentage reduction in residual area/h were evaluated over 12 h following addition of PMA (20 ng/ml); a selective COX-2 inhibitor, VU08 (1 µM); and specific eicosanoids in combinations and at concentrations indicated. Values represent linear regression of the slope (-{Delta} area/time) ± 95% confidence intervals. Differences in migration rate in the absence or presence of U46619 (third and fourth bars from the left) is significant (P < 0.05). b, dose response of TXA2 agonist, U46619, to reconstitute PMA-induced migration under COX-2-inhibited (VU08, 1 µM) conditions. Endothelial migration rates were evaluated as above (ED50 of ~0.1 µM). c, TXA2 receptor antagonist, SQ29548, blocks PMA-induced endothelial migration. Endothelial migration rates were evaluated for endothelial cells exposed to vehicle, PMA (20 ng/ml) or PMA supplemented with SQ29548 at concentrations indicated. a–c: columns, migration rates; bars, 95% confidence intervals.

 
Shown in Fig. 2bCitation , U46619 reconstituted PMA induced migration responses in the presence of COX-2 inhibition, with an ED50 in the range of 0.1–1.0 µM, consistent with its affinity for thromboxane receptors (20) . Importantly, Fig. 2cCitation shows the TXA2 receptor antagonist, SQ29548, blocked PMA-induced endothelial migration, with an IC50 of ~0.1 µM, also consistent with its reported affinity for thromboxane receptors (20) . U46619 alone did not stimulate migration rates above basal levels in the absence of PMA (data not shown), suggesting TXA2 participates as a requisite but permissive contributor to induced migration.

To test the hypothesis that TXA2 may be a mediator of angiogenic responses promoted by COX-2, we evaluated effects of systemic COX-2 inhibition upon corneal angiogenesis in a mouse pellet implantation model. Systemic administration of a selective COX-2 inhibitor imposed a marked inhibitory effect on the angiogenic response to basic FGF in the corneal model, reducing the area vascularized by 52% and the density of vascularity within that area by 80% (Fig. 3a)Citation . This provided strong evidence that a COX-2 metabolite participates in angiogenic responses to FGF.

Consistent with a role for TXA2, local administration of the TXA2 receptor antagonist, SQ29548, in the corneal pellet inhibited FGF-stimulated angiogenesis, reducing the vascularized area by 40% and the vascular density within that vascularized area by 51% (Fig. 3b)Citation . Although vascular flow in the ocular circulation is sensitive to TXA2 mimetics (21) , the response is vasoconstrictive, and the TXA2 receptor antagonist should promote vasodilatation and capillary filling rather than the attenuation we observed. Thus, TXA2 appears to function as an in vivo mediator of FGF-stimulated angiogenesis.

The action of the TXA2 agonist U46619 to reconstitute endothelial migration under COX-2-inhibited conditions (Fig. 2a)Citation suggested the possibility of reconstituting corneal angiogenic responses to bFGF in the setting of systemic COX-2 inhibition. Shown in Fig. 4Citation , locally administered U46619 showed a striking capacity to repair the attenuated angiogenic response seen in the setting of COX-2 inhibition, returning the vascularized area to 80% and the vascular density within that area to 95% of levels achieved with FGF in the absence of COX-2 inhibition. U46619 alone was not angiogenic, and it did not amplify on the bFGF response in animals with intact COX-2 function (vehicle).

These findings provide in vivo validation of a critical role for TXA2 in neovascularization responses. Extrapolation from the endothelial migration responses in vitro (Fig. 2a)Citation suggests that a critical threshold level of TXA2 is required to support angiogenesis in this system, one that is not met under non-COX-2-induced conditions. Although COX-2 induction may lead to endothelial production of TXA2, other cellular sources may be relevant in the context of neovascularization in specific tissue circumstances.

Platelets generate TXA2 from endogenous COX-1-derived substrate prostaglandin H2 and can convert endothelial-derived prostaglandin H2 to TXA2 (22) . We speculate that TXA2 from either source may support angiogenesis adjacent to microthrombi in tumors and other vascular sites. Indeed, reported effects of thromboxane synthase inhibitors and thromboxane receptor antagonists to inhibit metastatic behavior of tumor cells in mouse models were attributed to interruption of adhesive platelet interactions with tumor cells (23) . Our findings suggest that TXA2 axis antagonists may, alternatively, act primarily to inhibit endothelial responses to angiogenic peptides that are required for tumor vascularization and metastasis. TXA2 axis antagonists may retain antiangiogenic activity under circumstances in which COX-2 inhibition is ineffective in eliminating TXA2 production that is dependent upon COX-1-derived substrate.

Although TXA2 receptor null mice show no overt developmental vascularization defects or disorders of pregnancy, gestation, or delivery (24) , other critical mediators of neovascularization in mature animals, such as {alpha}vß3, are not required for developmental vascularization to proceed (25) . The requirement for thromboxane receptors to mediate COX-2 induced responses provides a focal point for intervention and a rationale for application of thromboxane receptor and synthase antagonists to potentiate therapeutic efficacy of COX-2 inhibitors.


   ACKNOWLEDGMENTS
 
Our thanks go to Ray Harris and Lee Limbird for critical reading of this manuscript.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by USPHS Awards RO1 DK38517 and P50 DK39261(to T. O. D.), CA47479 (to L. J. M.), and DK48831, GM42056, DK26657, and GM15431 (to J. D. M.) as well as a by a center grant from the National Cancer Institute (Grant CA68485) . J. D. M. is the recipient of a Burroughs-Wellcome Fund Clinical Scientist Award in Translational Research. The T. J. Martell Foundation provided support critical to this work. Back

2 To whom requests for reprints should be addressed, at Division of Nephrology, MCN S3223, Vanderbilt University Medical Center, Nashville, TN 37232-2372. Phone: (615) 343-8496; Fax: (615) 343-7156; E-mail: tom.daniel{at}mcmail.vanderbilt.edu Back

3 The abbreviations used are: COX-2, cyclooxygenase-2; FGF, fibroblast growth factor; bFGF, basic FGF; TXA2, thromboxane A2; PMA, phorbol myristate acetate. Back

Received 5/21/99. Accepted 8/ 2/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Majima M., Isono M., Ikeda Y., Hayashi I., Hatanaka K., Harada Y., Katsumata O., Yamashina S., Katori M., Yamamoto S. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn. J. Pharmacol., 75: 105-114, 1997.[Medline]
  2. Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.[Medline]
  3. Tsujii M., Kawano S., DuBois R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA, 94: 3336-3340, 1997.[Abstract/Free Full Text]
  4. Tsujii M., DuBois R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493-501, 1995.[Medline]
  5. Hla T., Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 89: 7384-7388, 1992.[Abstract/Free Full Text]
  6. Creminon C., Habib A., Maclouf J., Pradelles P., Grassi J., Frobert Y. Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays. Biochim. Biophys. Acta, 1254: 341-348, 1995.[Medline]
  7. Kage K., Fujita N., Oh-hara T., Ogata E., Fujita T., Tsuruo T. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem. Biophys. Res. Commun., 254: 259-263, 1999.[Medline]
  8. Schmedtje J. F. J., Ji Y. S., Liu W. L., DuBois R. N., Runge M. S. Hypoxia induces cyclooxygenase-2 via the NF-{kappa}B p65 transcription factor in human vascular endothelial cells. J. Biol. Chem., 272: 601-608, 1997.[Abstract/Free Full Text]
  9. Kito H., Yokoyama C., Inoue H., Tanabe T., Nakajima N., Sumpio B. E. Cyclooxygenase expression in bovine aortic endothelial cells exposed to cyclic strain. Endothelium, 6: 107-112, 1998.[Medline]
  10. Karim S., Habib A., Levy-Toledano S., Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J. Biol. Chem., 271: 12042-12048, 1996.[Abstract/Free Full Text]
  11. Blanco A., Habib A., Levy-Toledano S., Maclouf J. Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Biochem. J., 312: 419-423, 1995.
  12. Busija D. W., Thore C., Beasley T., Bari F. Induction of cyclooxygenase-2 following anoxic stress in piglet cerebral arteries. Microcirculation, 3: 379-386, 1996.[Medline]
  13. Matsumura K., Cao C., Ozaki M., Morii H., Nakadate K., Watanabe Y. Brain endothelial cells express cyclooxygenase-2 during lipopolysaccharide-induced fever: light and electron microscopic immunocytochemical studies. J. Neurosci., 18: 6279-6289, 1998.[Abstract/Free Full Text]
  14. McAdam B. F., Catella-Lawson F., Mardini I. A., Kapoor S., Lawson J. A., FitzGerald G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA, 96: 272-277, 1999.[Abstract/Free Full Text]
  15. Coffey R. J., Hawkey C. J., Damstrup L., Graves-Deal R., Daniel V. C., Dempsey P. J., Chinery R., Kirkland S. C., DuBois R. N., Jetton T. L., Morrow J. D. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. USA, 94: 657-662, 1997.[Abstract/Free Full Text]
  16. Stein E., Lane A. A., Cerretti D. P., Schoecklmann H. O., Schroff A. D., Van Etten R. L., Daniel T. O. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev., 12: 667-678, 1998.[Abstract/Free Full Text]
  17. Kenyon B. M., Voest E. E., Chen C. C., Flynn E., Folkman J., D’Amato R. J. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci., 37: 1625-1632, 1996.[Abstract/Free Full Text]
  18. Bustos M., Coffman T. M., Saadi S., Platt J. L. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. J. Clin. Invest., 100: 1150-1158, 1997.[Medline]
  19. Ishizuka T., Kawakami M., Hidaka T., Matsuki Y., Takamizawa M., Suzuki K., Kurita A., Nakamura H. Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM- 1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin. Exp. Immunol., 112: 464-470, 1998.[Medline]
  20. Armstrong R. A., Wilson N. H. Aspects of the thromboxane receptor system. Gen. Pharmacol., 26: 463-472, 1995.[Medline]
  21. Krauss A. H., Woodward D. F., Burk R. M., Gac T. S., Gibson L. L., Protzman C. E., Abbass F., Marshall K., Senior J. Pharmacological evidence for thromboxane receptor heterogeneity: implications for the eye. J. Ocular Pharmacol. Ther., 13: 303-312, 1997.[Medline]
  22. Camacho M., Lopez-Belmonte J., Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ. Res., 83: 353-365, 1998.[Abstract/Free Full Text]
  23. Honn K. V. Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin. Exp. Metastasis, 1: 103-114, 1983.[Medline]
  24. Thomas D. W., Mannon R. B., Mannon P. J., Latour A., Oliver J. A., Hoffman M., Smithies O., Koller B. H., Coffman T. M. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J. Clin. Invest., 102: 1994-2001, 1998.[Medline]
  25. Bader B. L., Rayburn H., Crowley D., Hynes R. O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all {alpha}v integrins. Cell, 95: 507-519, 1998.[Medline]



This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
M. Sahin, E. Sahin, and S. Gumuslu
Cyclooxygenase-2 in Cancer and Angiogenesis
Angiology, April 1, 2009; 60(2): 242 - 253.
[Abstract] [PDF]

Home page
 Neuro OncolHome page
S. Kesari, D. Schiff, L. Doherty, D. C. Gigas, T. T. Batchelor, A. Muzikansky, A. O'Neill, J. Drappatz, A. S. Chen-Plotkin, N. Ramakrishna, et al.
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Neuro-oncol, July 1, 2007; 9(3): 354 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. Kamoshita, Y. Ikeda, M. Fujita, H. Amano, A. Oikawa, T. Suzuki, Y. Ogawa, S. Yamashina, S. Azuma, S. Narumiya, et al.
Recruitment of a Prostaglandin E Receptor Subtype, EP3-Expressing Bone Marrow Cells Is Crucial in Wound-Induced Angiogenesis
Am. J. Pathol., October 1, 2006; 169(4): 1458 - 1472.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
S. Pal, J. Wu, J. K. Murray, S. H. Gellman, M. A. Wozniak, P. J. Keely, M. E. Boyer, T. M. Gomez, S. M. Hasso, J. F. Fallon, et al.
An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis
J. Cell Biol., September 25, 2006; 174(7): 1047 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. de Leval, T. Dassesse, J.-M. Dogne, D. Waltregny, A. Bellahcene, V. Benoit, B. Pirotte, and V. Castronovo
Evaluation of Original Dual Thromboxane A2 Modulators as Antiangiogenic Agents
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1057 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. Alfranca, M. A. Iniguez, M. Fresno, and J. M. Redondo
Prostanoid signal transduction and gene expression in the endothelium: Role in cardiovascular diseases
Cardiovasc Res, June 1, 2006; 70(3): 446 - 456.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
W. Yan and H.-H. Tai
Glycogen Synthase Kinase-3 Phosphorylation, T-Cell Factor Signaling Activation, and Cell Morphology Change following Stimulation of Thromboxane Receptor {alpha}
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 267 - 274.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Michel, J.-S. Silvestre, L. Waeckel, S. Corda, T. Verbeuren, J. P. Vilaine, M. Clergue, M. Duriez, and B. I. Levy
Thromboxane A2/Prostaglandin H2 Receptor Activation Mediates Angiotensin II-Induced Postischemic Neovascularization
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 488 - 493.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Quiniou, F. Sennlaub, M. H. Beauchamp, D. Checchin, I. Lahaie, S. Brault, F. Gobeil Jr., M. Sirinyan, A. Kooli, P. Hardy, et al.
Dominant Role for Calpain in Thromboxane-Induced Neuromicrovascular Endothelial Cytotoxicity
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 618 - 627.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. R. Howe, S.-H. Chang, K. C. Tolle, R. Dillon, L. J.T. Young, R. D. Cardiff, R. A. Newman, P. Yang, H. T. Thaler, W. J. Muller, et al.
HER2/neu-Induced Mammary Tumorigenesis and Angiogenesis Are Reduced in Cyclooxygenase-2 Knockout Mice
Cancer Res., November 1, 2005; 65(21): 10113 - 10119.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
F. Fanfani, A. Fagotti, G. Ferrandina, G. Bifulco, F. Legge, D. Lorusso, L. Minelli, and G. Scambia
Increased cyclooxygenase-2 expression is associated with better clinical outcome in patients submitted to complete ablation for severe endometriosis
Hum. Reprod., October 1, 2005; 20(10): 2964 - 2968.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Bradbury, D. Clarke, C. Seedhouse, L. Corbett, J. Stocks, and A. Knox
Vascular Endothelial Growth Factor Induction by Prostaglandin E2 in Human Airway Smooth Muscle Cells Is Mediated by E Prostanoid EP2/EP4 Receptors and SP-1 Transcription Factor Binding Sites
J. Biol. Chem., August 26, 2005; 280(34): 29993 - 30000.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Brown and R. N. DuBois
COX-2: A Molecular Target for Colorectal Cancer Prevention
J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M.L. Hull, A. Prentice, D.Y. Wang, R.P. Butt, S.C. Phillips, S.K. Smith, and D.S. Charnock-Jones
Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis
Hum. Reprod., February 1, 2005; 20(2): 350 - 358.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Dannenberg, S. M. Lippman, J. R. Mann, K. Subbaramaiah, and R. N. DuBois
Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
J. Clin. Oncol., January 10, 2005; 23(2): 254 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
A. W. Ashton and J. A. Ware
Thromboxane A2 Receptor Signaling Inhibits Vascular Endothelial Growth Factor-Induced Endothelial Cell Differentiation and Migration
Circ. Res., August 20, 2004; 95(4): 372 - 379.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
A. W. Ashton, Y. Cheng, A. Helisch, and J. A. Ware
Thromboxane A2 Receptor Agonists Antagonize the Proangiogenic Effects of Fibroblast Growth Factor-2: Role of Receptor Internalization, Thrombospondin-1, and {alpha}v{beta}3
Circ. Res., April 2, 2004; 94(6): 735 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
R. S. Sellers, L. Silverman, and K. N. M. Khan
Cyclooxygenase-2 Expression in the Cornea of Dogs with Keratitis
Vet. Pathol., March 1, 2004; 41(2): 116 - 121.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
T. KUWANO, S. NAKAO, H. YAMAMOTO, M. TSUNEYOSHI, T. YAMAMOTO, M. KUWANO, and M. ONO
Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis
FASEB J, February 1, 2004; 18(2): 300 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. P. Remmel, B. C. Crews, K. R. Kozak, A. S. Kalgutkar, and L. J. Marnett
STUDIES ON THE METABOLISM OF THE NOVEL, SELECTIVE CYCLOOXYGENASE-2 INHIBITOR INDOMETHACIN PHENETHYLAMIDE IN RAT, MOUSE, AND HUMAN LIVER MICROSOMES: IDENTIFICATION OF ACTIVE METABOLITES
Drug Metab. Dispos., January 1, 2004; 32(1): 113 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Sengupta, L. A. Sellers, T. Cindrova, J. Skepper, E. Gherardi, R. Sasisekharan, and T.-P. D. Fan
Cyclooxygenase-2-selective Nonsteroidal Anti-Inflammatory Drugs Inhibit Hepatocyte Growth Factor/Scatter Factor-induced Angiogenesis
Cancer Res., December 1, 2003; 63(23): 8351 - 8359.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. Wu, A. P. Mannam, J. Wu, S. Kirbis, J.-L. Shie, C. Chen, R. J. Laham, F. W. Sellke, and J. Li
Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF
Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2420 - H2429.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A E Koch
Angiogenesis as a target in rheumatoid arthritis
Ann Rheum Dis, November 1, 2003; 62(90002): ii60 - 67.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Choy and L. Milas
Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?
J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. G. Buchanan, D. Wang, F. Bargiacchi, and R. N. DuBois
Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor
J. Biol. Chem., September 12, 2003; 278(37): 35451 - 35457.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
T. Sakurai, K. Tamura, S. Okamoto, T. Hara, and H. Kogo
Possible Role of Cyclooxygenase II in the Acquisition of Ovarian Luteal Function in Rodents
Biol Reprod, September 1, 2003; 69(3): 835 - 842.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Miyata, S. Koga, S. Kanda, M. Nishikido, T. Hayashi, and H. Kanetake
Expression of Cyclooxygenase-2 in Renal Cell Carcinoma: Correlation with Tumor Cell Proliferation, Apoptosis, Angiogenesis, Expression of Matrix Metalloproteinase-2, and Survival
Clin. Cancer Res., May 1, 2003; 9(5): 1741 - 1749.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
H. Amano, I. Hayashi, H. Endo, H. Kitasato, S. Yamashina, T. Maruyama, M. Kobayashi, K. Satoh, M. Narita, Y. Sugimoto, et al.
Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth
J. Exp. Med., January 20, 2003; 197(2): 221 - 232.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. RODRIGUES, E. VAN AKEN, S. VAN BOCXLAER, S. ATTOUB, Q.-D. NGUYEN, E. BRUYNEEL, B. R. WESTLEY, F. E. B. MAY, L. THIM, M. MAREEL, et al.
Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling
FASEB J, January 1, 2003; 17(1): 7 - 16.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Dormond, M. Bezzi, A. Mariotti, and C. Ruegg
Prostaglandin E2 Promotes Integrin alpha Vbeta 3-dependent Endothelial Cell Adhesion, Rac-activation, and Spreading through cAMP/PKA-dependent Signaling
J. Biol. Chem., November 22, 2002; 277(48): 45838 - 45846.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Cheng, D. M. Brantley, H. Liu, Q. Lin, M. Enriquez, N. Gale, G. Yancopoulos, D. P. Cerretti, T. O. Daniel, and J. Chen
Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis
Mol. Cancer Res., November 1, 2002; 1(1): 2 - 11.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K.-i. Sunayama, H. Konno, T. Nakamura, H. Kashiwabara, T. Shoji, T. Tsuneyoshi, and S. Nakamura
The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC{Delta}474 knockout mice
Carcinogenesis, August 1, 2002; 23(8): 1351 - 1359.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Davies, L.-A. Martin, N. Sacks, and M. Dowsett
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention
Ann. Onc., May 1, 2002; 13(5): 669 - 678.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Kitahara, F. Eitner, T. Ostendorf, U. Kunter, U. Janssen, R. Westenfeld, K. Matsui, D. Kerjaschki, and J. Floege
Selective Cyclooxygenase-2 Inhibition Impairs Glomerular Capillary Healing in Experimental Glomerulonephritis
J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1261 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. M. Leahy, R. L. Ornberg, Y. Wang, B. S. Zweifel, A. T. Koki, and J. L. Masferrer
Cyclooxygenase-2 Inhibition by Celecoxib Reduces Proliferation and Induces Apoptosis in Angiogenic Endothelial Cells in Vivo
Cancer Res., February 1, 2002; 62(3): 625 - 631.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
U. Huynh-Do, C. Vindis, H. Liu, D. P. Cerretti, J. T. McGrew, M. Enriquez, J. Chen, and T. O. Daniel
Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis
J. Cell Sci., January 8, 2002; 115(15): 3073 - 3081.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Pradono, R. Tazawa, M. Maemondo, M. Tanaka, K. Usui, Y. Saijo, K. Hagiwara, and T. Nukiwa
Gene Transfer of Thromboxane A2 Synthase and Prostaglandin I2 Synthase Antithetically Altered Tumor Angiogenesis and Tumor Growth
Cancer Res., January 1, 2002; 62(1): 63 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Bing, M. Miyataka, K. A. Rich, N. Hanson, X. Wang, H. D. Slosser, and S.-R. Shi
Nitric Oxide, Prostanoids, Cyclooxygenase, and Angiogenesis in Colon and Breast Cancer
Clin. Cancer Res., November 1, 2001; 7(11): 3385 - 3392.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
S. T. Davidge
Prostaglandin H Synthase and Vascular Function
Circ. Res., October 12, 2001; 89(8): 650 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
R. A. Stockton and B. S. Jacobson
Modulation of Cell-Substrate Adhesion by Arachidonic Acid: Lipoxygenase Regulates Cell Spreading and ERK1/2-inducible Cyclooxygenase Regulates Cell Migration in NIH-3T3 Fibroblasts
Mol. Biol. Cell, July 1, 2001; 12(7): 1937 - 1956.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
M. H. Beauchamp, A. K. Martinez-Bermudez, F. Gobeil Jr., A. M. Marrache, X. Hou, G. Speranza, D. Abran, C. Quiniou, P. Lachapelle, J. Roberts II, et al.
Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy
J Appl Physiol, June 1, 2001; 90(6): 2279 - 2288.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A. E. Koch
The role of angiogenesis in rheumatoid arthritis: recent developments
Ann Rheum Dis, November 1, 2000; 59(90001): i65 - 71.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daniel, T. O.
Right arrow Articles by Marnett, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daniel, T. O.
Right arrow Articles by Marnett, L. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online